B
Bull
Bull · 25%MIST
$2.13
Scenario price
$0.693
-0.072 (-10.36%)At close
Loading chart…
- High
- 0.785
- Open
- 0.761
- VWAP
- 0.72
- Volume
- 1.19M
- Mkt Cap
- 68.71M
- Low
- 0.675
- Amount
- 856.11K
- EV/EBITDA, TTM
- -0.08
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
AI analysis of Milestone Pharmaceuticals Inc (MIST)
BuyMilestone Pharmaceuticals Inc is a good buy right now due to its recent approval for etripamil in China, which triggered a $2 million milestone payment and opens up a significant market opportunity. The current price is $0.7268, and analysts project a price target of $3, suggesting a potential upside of approximately 313%. Additionally, the stock has shown a 5-day change of +12.79%, indicating positive momentum. However, the main risk is the company's substantial net losses, with a net income of -$28,614,000 in Q2 2026.
Valuation Metrics
The current forward P/E ratio for Milestone Pharmaceuticals Inc (MIST) is 0.00, compared to its 5-year average forward P/E of -2.72.
Alphio AI Price Scenarios for MIST
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
5.011-04NewsfilterMilestone Pharmaceuticals Grants 33,000 Stock Options to New Employee
9.009-27NASDAQ.COMMilestone Pharmaceuticals Initiates Phase 3 Trial for Etripamil
9.009-03NASDAQ.COMMilestone Pharmaceuticals Secures Approval for Etripamil in China
- 8.509-03Newsfilter
Everest Medicines to Lead Etripamil Commercialization in Greater China
9.008-21NASDAQ.COMMilestone Pharmaceuticals Initiates Pivotal Phase 3 Trial for Etripamil in AFib-RVR
MIST FAQ — answered by Alphio AI
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Milestone Pharmaceuticals Inc is a good buy right now due to its recent approval for etripamil in China, which triggered a $2 million milestone payment and opens up a significant market opportunity. The current price is $0.7268, and analysts project a price target of $3, suggesting a potential upside of approximately 313%. Additionally, the stock has shown a 5-day change of +12.79%, indicating positive momentum. However, the main risk is the company's substantial net losses, with a net income of -$28,614,000 in Q2 2026.
Community
More ↗No posts yet
Sign up or log in to join the discussionRelated articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.